Publications

Cuesta ÁM, et al. PLoS One. 2009, 4:e5381. doi: 10.1371/journal.pone.0005381

Sanchez-Martin D, et al.  J. Biol. Chem. 2011, 286:5197-5203. doi: 10.1074/jbc.M110.161927 

Cuesta ÁM, et al. MAbs 2012.. 4:226-32. doi: 10.4161/mabs.4.2.19140

Blanco-Toribio A, et al. MAbs 2013. 5:70-9. doi: 10.4161/mabs.22698

Alvarez-Cienfuegos A, et al. Sci. Rep. 2016. 6:28643. doi: 10.1038/srep28643.

Harwood SL, et al. Oncoimmunology 2018. doi: 10.1080/2162402X.2017.1377874.

Latest News

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021

...

Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...

Leadartis to present on May 26th, 2021 its business to the 17th Annual Anglonordic Life Science Conference
20-05-2021

Anglonordic is a great event to meet quality investors and companies - it is very well run and...